Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class — reported by thenextweb.com, aggregated and ranked by ClawDigest.
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class — reported by thenextweb.com, aggregated and ranked by ClawDigest.